BTX's subsidiary LifeMap has been doing big data for a few years. I do think this is a big deal, taking the first big step with people from AI world. BTX at this point is still a very small piece of the puzzle, but the puzzle we are talking about here is truely revolutionary. West was smart to buy up Gerons hESC as well as ACTC's pure stem. A visionary no doubt.
The venue of Mensa 2016 was chosen in order to discuss the ongoing paradigm shift relating to the use of artificially-intelligent systems to surpass human performance in areas including image recognition, autonomous driving, and biomedical research. Dr. West's presentation along with a video describing AI-based discovery and iTR will be available on BioTime's website in the Events & Presentations section under Investors & Media.
Mensa, the high IQ society, provides a forum for intellectual exchange among its members in over 100 countries around the world.
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 29, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr. Michael D. West, will give a lecture at the Mensa Annual Gathering today titled, "Hayflick Rewound: Implications of Reversing the Aging of Human Cells." Dr. West will discuss the impact of aging on society, as well as fundamental advances in understanding its causes and strategies to intervene using regenerative medicine. Dr. West will describe an online Artificial Intelligence (AI) and Deep Learning (DL) resource called "Embryonic.AI" being launched this week by LifeMap Sciences, Inc., a BioTime subsidiary, for beta testing and designed to discover novel treatments that cause the body to scarlessly repair tissue damage, an emerging field called induced Tissue Regeneration (iTR).
So the goal at the outset isn't really to grow people in a lab, but rather to push the science of genetic engineering higher while bringing costs lower. In addition, the authors say that the project can yield other benefits: "Potential applications include growing transplantable human organs; engineering immunity to viruses in cell lines via genome-wide recoding; engineering cancer resistance into new therapeutic cell lines; and accelerating high-productivity, cost-efficient vaccine and pharmaceutical development using human cells and organoids."
The authors, led by geneticist Jef Boeke of the New York University Langone Medical Center, also write that one of the pilot projects they're considering is using stem cells to create an "ultrasafe" human cell line.
Over this year there has been much talk about the revolutionary gene editing technique called CRISPR, and now top scientists from Shanghai, Harvard, Cambridge, etc are talking about combining this gene editing with stem cells for both research and therapeutic purposes.
I Would think BTX is in a very lucrative position with over 800 stem cell patents. Also, their subsidiary LifeMaps is a leader in big data & genetics.
Excerpt from Scientific America:
How does the model work?
Heart disease and high cholesterol are associated with certain gene mutations. We introduce these gene mutations into human pluripotent stem cells, which are master cells that can produce every other kind of cell in the body, such as neurons or liver cells. The stem cells are either taken from human blastocysts—the term for a very early stage embryo, not yet attached to the wall of the womb—with consent from a donor, or reprogrammed from somatic cells—a different kind of cell that includes blood cells. We can then study these mutations and different ways of treating them outside of the body, for example, in petri dishes.
Biotimes first product to hit clinical trials is Renevia. Renevia is a patented device/procedure using a hydrogel composed of hyralonic acid and collagen which is then implanted and along with a patient's own adipose(fat) stem cells.
Renevia is in stage three and has so far shown good results. If successful could be THE standard product used for next-gen cosmetic surgery industry.
As far as i know this is not one a Biotime subsidiary product, if so BTX will see a huge stock increase at the time of it's release later this year.
Buy rating: BUY
....meaning great buying opportunity. And don't deny it destclown aka baltbear....THERE IS a reason you keep coming back after all these years!
BIotima and it's subsidiaries are going full throttle into the clinical trial phase. They need cash to fund these trials. BTX has a very extensive biz structure that doesn't want to get too thin. Multi-tasking many multi-million dollar programs; AMD, next-gen cancer diagnostics, industry standard products for the next-gen cosmetic surgery field, spine and bone regeneration, and oh yeah, two types of cancer vaccines.
Potential here is tremendous, even if just one of these programs becomes successful.
BTX has very little debt, most trials are being funded by institutions like the Cancer institute of Spain, Wistar Cancer institute, NIH and many more.
The positive take away here is that the sold shares are going right back into the company and not to pay off big pharma, or selling off IP. BTX is majority holder in all of its subsidiaries and
holds the key(profits) to it's own future.